Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.72 [0.57, 0.91] | | < 1 | | 67% | 2 studies (2/-) | 99.7 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.62 [0.51, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
PFS (extension) | 0.60 [0.48, 0.74] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.69 [0.54, 0.88] | | < 1 | | 75% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | important | - |
DCR | 1.99 [1.24, 3.18] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 5.41 [0.29, 101.82] | | > 1 | | 78% | 2 studies (2/-) | 86.8 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 1.93 [1.10, 3.38] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.10 [0.75, 1.62] | | < 1 | | 0% | 1 study (1/-) | 30.7 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.65 [0.37, 1.12] | | < 1 | | 0% | 1 study (1/-) | 94.0 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.93 [0.45, 1.92] | | < 1 | | 0% | 1 study (1/-) | 57.7 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 0.69 [0.29, 1.66] | | < 1 | | 0% | 1 study (1/-) | 79.5 % | NA | not evaluable | | non important | - |
SAE (any grade) | 0.75 [0.52, 1.10] | | < 1 | | 0% | 1 study (1/-) | 92.6 % | NA | not evaluable | | non important | - |
SAE (grade 3-4) | 0.92 [0.61, 1.40] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 2.00 [1.54, 2.59] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 1.85 [1.39, 2.48] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 2.12 [1.60, 2.79] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 1.84 [1.51, 2.23] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 2.05 [0.40, 10.53] | | < 1 | | 15% | 2 studies (2/-) | 19.5 % | low | not evaluable | high | non important | - |
TRAE leading to discontinuation (any grade) | 1.81 [1.46, 2.26] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 1.49 [0.51, 4.32] | | < 1 | | 56% | 2 studies (2/-) | 23.4 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Anaemia TRAE (grade 3-4) | 2.27 [1.34, 3.84] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.68 [0.26, 1.81] | | < 1 | | 0% | 1 study (1/-) | 77.8 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 1.13 [0.55, 2.32] | | < 1 | | 0% | 2 studies (2/-) | 37.0 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.46 [0.87, 2.46] | | < 1 | | 0% | 2 studies (2/-) | 7.7 % | some concern | not evaluable | moderate | non important | - |
Endocrine disorders TRAE (grade 3-4) | 9.86 [0.54, 180.88] | | < 1 | | 0% | 1 study (1/-) | 6.4 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.32 [0.46, 3.78] | | < 1 | | 34% | 2 studies (2/-) | 30.5 % | some concern | not evaluable | moderate | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 1.73 [1.04, 2.86] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 1.81 [0.97, 3.36] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 2.33 [0.86, 6.29] | | < 1 | | 0% | 2 studies (2/-) | 4.8 % | some concern | not evaluable | moderate | non important | - |
Increased ALT TRAE (grade 3-4) | 1.15 [0.38, 3.55] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
Increased lipase level TRAE (grade 3-4) | 2.87 [1.61, 5.12] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.01 [0.54, 1.90] | | < 1 | | 0% | 2 studies (2/-) | 48.3 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 1.29 [0.96, 1.72] | | < 1 | | 0% | 1 study (1/-) | 4.5 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.81 [0.67, 4.92] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.40 [0.80, 2.44] | | < 1 | | 0% | 1 study (1/-) | 11.9 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 1.12 [0.54, 2.32] | | < 1 | | 0% | 1 study (1/-) | 37.6 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Renal and urinary disorders TRAE (grade 3-4) | 5.92 [0.71, 49.31] | | < 1 | | 0% | 1 study (1/-) | 5.1 % | NA | not evaluable | | non important | - |
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 13.96 [1.83, 106.45] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.36 [1.79, 10.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.44 [0.71, 2.95] | | < 1 | | 0% | 1 study (1/-) | 15.6 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.69 [0.37, 1.29] | | < 1 | | 0% | 1 study (1/-) | 87.8 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 1.14 [0.43, 3.04] | | < 1 | | 0% | 1 study (1/-) | 39.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.97 [0.54, 1.75] | | < 1 | | 0% | 1 study (1/-) | 53.7 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 2.48 [0.54, 11.47] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.73 [0.12, 4.41] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.54 [0.20, 1.42] | | < 1 | | 0% | 1 study (1/-) | 89.5 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 1.96 [0.22, 17.71] | | < 1 | | 0% | 1 study (1/-) | 27.5 % | NA | not evaluable | | non important | - |
Dyspepsia AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.96 [0.09, 43.66] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.29 [0.07, 1.21] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.48 [0.47, 4.67] | | < 1 | | 0% | 1 study (1/-) | 25.2 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 1.31 [0.34, 5.00] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.24 [0.02, 2.68] | | < 1 | | 0% | 1 study (1/-) | 87.4 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 1.47 [0.15, 14.22] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.65 [0.14, 2.92] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |